Nutraceuticals and prostate cancer prevention: A current review

Nature Reviews Urology

Volumn 7, Issue 1, 2010, Pages 21-30

  Trottier, Greg ^a   Boström, Peter J ^a   Lawrentschuk, Nathan ^a   Fleshner, Neil E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAROTENOID; CATECHIN; COLECALCIFEROL; EPIGALLOCATECHIN GALLATE; GAMMA TOCOPHEROL; GENISTEIN; ISOFLAVONE; LYCOPENE; POMEGRANATE EXTRACT; SELENIUM; SILYMARIN; VITAMIN D;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FATIGUE; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; NUTRITION; ORCHIECTOMY; POMEGRANATE JUICE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SOYBEAN; SUNLIGHT; TEA; TOMATO; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 75949093244     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.234     Document Type: Review

References (100)

1. Shimizu, H. et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63, 963-966 (1991).
2. Kalra, E. K. Nutraceutical-definition and Introduction. AAPS Pharm Sci. 5, E25 (2003).
3. Health Canada. http://www.hc-sc.gc.ca/fn-an/ label-etiquet/claims-reclam/ nutra-funct-foods-nutra-fonct-aliment-eng.php, accessed August 26th 2009 (Ottawa, 1998).
4. Lippert, M. C., McClain, R., Boyd, J. C. & Theodorescu, D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86, 2642-2648 (1999).
5. Nam, R. K. et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J. Urol. 161, 1521-1524 (1999).
6. Hamilton, R. J. & Freedland, S. J. Rationale for statins in the chemoprevention of prostate cancer. Curr. Urol. Rep. 9, 189-196 (2008).
7. Rittmaster, R. S., Fleshner, N. E. & Thompson, I. M. Pharmacological approaches to reducing the risk of prostate cancer. Eur. Urol. 55, 1064-1073 (2009).
8. Colli, J. L. & Amling, C. L. Chemoprevention of prostate cancer: what can be recommended to patients? Curr. Urol. Rep. 10, 165-171 (2009).
9. Schwartz, G. G. Vitamin D and the epidemiology of prostate cancer. Semin. Dial. 18, 276-289 (2005).
10. Krishnan, A., Peehl, D. & Feldman, D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell Biochem. 88, 363-371 (2003).
11. Schwartz, G. & Hulka, B. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10, 1307-1311 (1990).
12. Hanchette, C. & Schwartz, G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70, 2861-2869 (1992).
13. Kafadar, K. Geographic trends in prostate cancer mortality: an application of spatial smoothers and the need for adjustment. Ann. Epidemiol. 7, 35-45 (1997).
14. Grant, W. An estimate of premature cancer mortality in the U. S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94, 1867-1875 (2002).
15. Schwartz, G. & Hanchette, C. U V, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 17, 1091-1101 (2006).
16. Di Silverio, F. , La Pera, G. & Tenaglia, R. Age-adjusted mortality rate and regional distribution for prostatic carcinoma in italy between 1969 and 1978. Prostate 3, 631-636 (1982).
17. John, E., Dreon, D., Koo, J. & Schwartz, G. residential sunlight exposure is associated with a decreased risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90, 549-552 (2004).
18. John, E., Schwartz, G., Koo, J., Van Den Berg, D. & Ingles, S. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. ancer Res. 65, 5470-5479 (2005).
19. Nomura, A. et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9, 425-432 (1998).
20. Gann, P. et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 5, 121-126 (1996).
21. Jacobs, E. et al. Plasma levels of 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D and the risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90, 533-537 (2004).
22. Platz, E., Leitzmann, M., Hollis, B., Willett, W. & Giovannucci, E. Plasma 1, 25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15, 255-265 (2004).
23. Corder, E. et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 2, 467-472 (1993).
24. Ahonen, M., Tenkanen, L., Teppo, L., Hakama, M. & Tuohimaa, P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847-852 (2000).
25. Tuohimaa, P. et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108, 104-108 (2004).
26. Ma, J. et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomarkers Prev. 7, 385-390 (1998).
27. Li, H. et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 4, e103 (2007).
28. Ahn, J. et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J. Natl Cancer Inst. 100, 796-804 (2008).
29. Vieth, R. Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Ann. Epidemiol. 19, 441-445 (2009).
30. Garland, C., Gorham, E., Mohr, S. & Garland, F. Vitamin D for cancer prevention: global perspective. Ann. Epidemiol. 19, 468-483 (2009).
31. Chen, T. C., Holick, M. F. , Lokeshwar, B. L., Burnstein, K. L. & Schwartz, G. G. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 164, 273-288 (2003).
32. Newsom-Davis, T., Kenny, L., Ngan, S., King, J. & Waxman, J. The promiscuous receptor. BJU Int. 104, 1204-1207 (2009).
33. Beer, T. et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 25, 669-674 (2007).
34. Constantinou, C., Papas, A. & Constantinou, A. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 123, 739-752 (2008).
35. Berrino, F. & Muti, P. Mediterranean diet and cancer. Eur. J. Clin. Nutr. 43 (Suppl. 2), 49-55 (1989).
36. Eichholzer, M., Stähelin, H., Gey, K., Lüdin, E. & Bernasconi, F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int. J. Cancer 66, 145-150 (1996).
37. Chan, J. et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 8, 893-899 (1999).
38. Kirsh, V. et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J. Natl Cancer Inst. 98, 245-254 (2006).
39. rodriguez, C. et al. Vitamin E supplements and risk of prostate cancer in U. S. men. Cancer Epidemiol. Biomarkers Prev. 13, 378-382 (2004).
40. Wright, M. et al. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol. Biomarkers Prev. 16, 1128-1135 (2007).
41. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330, 1029-1035 (1994).
42. Heinonen, O. et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl Cancer Inst. 90, 440-446 (1998).
43. Lippman, S. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51 (2009).
44. Gaziano, J. et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study ii randomized controlled trial. JAMA 301, 52-62 (2009).
45. Di Mascio, P. , Kaiser, S. & Sies, H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch. Biochem. Biophys. 274, 532-538 (1989).
46. Wertz, K., Siler, U. & Goralczyk, R. Lycopene: modes of action to promote prostate health. Arch. Biochem. Biophys. 430, 127-134 (2004).
47. Mills, P. K., Beeson, W. L., Phillips, R. L. & Fraser, G. E. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64, 598-604 (1989).
48. Etminan, M., Takkouche, B. & Caamano-isorna, F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol. Biomarkers Prev. 13, 340-345 (2004).
49. Giovannucci, E. et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 87, 1767-1776 (1995).
50. Giovannucci, E., Rimm, E. B., Liu, Y., Stampfer, M. J. & Willett, W. C. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl Cancer Inst. 94, 391-398 (2002).
51. Gartner, C., Stahl, W. & Sies, H. Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Am. J. Clin. Nutr. 66, 116-122 (1997).
52. Stahl, W. & Sies, H. Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato Juice in humans. J. Nutr. 122, 2161-2166 (1992).
53. Gann, P. H. et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59, 1225-1230 (1999).
54. Kirsh, V. A. et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 92-98 (2006).
55. Peters, U. et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, ung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 16, 962-968 (2007).
56. Key, T. J. et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective investigation into Cancer and Nutrition study. Am. J. Clin. Nutr. 86, 672-681 (2007).
57. Kavanaugh, C. J., Trumbo, P. R. & Ellwood, K. C. The U. S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J. Natl Cancer Inst. 99, 1074-1085 (2007).
58. Chen, L. et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food ntervention. J. Natl Cancer Inst. 93, 1872-1879 (2001).
59. Kim, H. S. et al. Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr. Cancer 47, 40-47 (2003).
60. Kucuk, O. et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 10, 861-868 (2001).
61. Ansari, M. S. & Gupta, N. P. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int. 92, 375-378 (2003).
62. Clark, P. E. et al. Phase I-II prospective doseescalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67, 1257-1261 (2006).
63. Ansari, M. S. & Gupta, N. P. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol. Oncol. 22, 415-420 (2004).
64. Jatoi, A. et al. A tomato-based, lycopene-containing intervention for androgen-ndependent prostate cancer: results of a Phase ii study from the North Central Cancer Treatment Group. Urology 69, 289-294 (2007).
65. Schwenke, C, Ubrig, B., Thurmann, P., Eggersmann, C. & Roth, S. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study. J. Urol. 181, 1098-1103 (2009).
66. Matlaga, B. R., Hall, M. C., Stindt, D. & Torti, F. M. Response of hormone refractory prostate cancer to lycopene. J. Urol. 166, 613 (2001).
67. Jian, L. Soy, isoflavones, and prostate cancer. Mol. Nutr. Food Res. 53, 217-226 (2009).
68. Hamilton-reeves, J. M., Rebello, S. A., Thomas, W., Slaton, J. W. & Kurzer, M. S. Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer. J. Nutr. 137, 2258-2263 (2007).
69. Swami, S. et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int. J. Cancer 124, 2050-2059 (2009).
70. Yan, L. & Spitznagel, E. L. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am. J. Clin. Nutr. 89, 1155-1163 (2009).
71. Urban, D. et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J. Urol. 165, 294-300 (2001).
72. Adams, K. F. , Chen, C., Newton, K. M., Potter, J. D. & Lampe, J. W. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol. Biomarkers Prev. 13, 644-648 (2004).
73. Dalais, F. S. et al. Effects of a diet rich in phytestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 64, 510-515 (2004).
74. Spentzos, D. et al. Minimal effect of a low-fat/ high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin. Cancer Res. 9, 3282-3287 (2003).
75. Kumar, N. B. et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 59, 141-147 (2004).
76. Hussain, M. et al. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 47, 111-117 (2003).
77. deVere White, R. W. et al. Effects of a genisteinrich extract on PSA levels in men with a history of prostate cancer. Urology 63, 259-263 (2004).
78. Hamilton-reeves, J. M., Rebello, S. A., Thomas, W., Kurzer, M. S. & Slaton, J. W. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr. Cancer 60, 7-13 (2008).
79. Adhami, V. M. & Mukhtar, H. Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer. Mol. Biotechnol. 37, 52-57 (2007).
80. Syed, D. N., Suh, Y. , Afaq, F. & Mukhtar, H. Dietary agents for chemoprevention of prostate cancer. Cancer Lett. 265, 167-176 (2008).
81. Severson, R. K., Nomura, A. M., Grove, J. S. & Stemmermann, G. N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 49, 1857-1860 (1989).
82. Kikuchi, N. et al. No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br. J. Cancer 95, 371-373 (2006).
83. Kurahashi, N., Sasazuki, S., Iwasaki, M., Inoue, M. & Tsugane, S. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am. J. Epidemiol. 167, 71-77 (2008).
84. Allen, N. E. et al. A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 15, 911-920 (2004).
85. Jian, L., Xie, L. P. , Lee, A. H. & Binns, C. W. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int. J. Cancer 108, 130-135 (2004).
86. Sonoda, T. et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 95, 238-242 (2004).
87. Bettuzzi, S. et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 66, 1234-1240 (2006).
88. Brausi, M., Rizzi, F. & Bettuzzi, S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur. Urol. 54, 472-473 (2008).
89. Jatoi, A. et al. A phase ii trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97, 1442-1446 (2003).
90. Choan, E. et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/ alternative therapy approach. Urol. Oncol. 23, 108-113 (2005).
91. Fleshner, N. et al. Randomized trial of Combination Vitamin E, Selenium, and Soy Protein among men with high grade prostatic intraepithelial neoplasia (HGPIN). J. Urol. 181, S263 (2009).
92. Van Patten, C. L., de Boer, J. G. & Tomlinson Guns, E. S. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J. Urol. 180, 2314-2321 (2008).
93. Lansky, E. P. & Newman, R. A. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J. Ethnopharmacol. 109, 177-206 (2007).
94. Pantuck, A. J. et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin. Cancer Res. 12, 4018-4026 (2006).
95. Gann, P. H. Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, cause. JAMA 301, 102-103 (2009).
96. Lawlor, D. A., Davey Smith, G., Bruckdorfer, K. R., Kundu, D. & Ebrahim, S. Observational versus randomised trial evidence. Lancet 364, 755 (2004).
97. Ornish, D. et al. Intensive lifestyle changes may affect the progression of prostate cancer. J. Urol. 174, 1065-1069 (2005).
98. Vaishampayan, U. et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 59, 1-7 (2007).
99. Kranse, R. et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int. J. Cancer 113, 835-840 (2005).
100. Schroder, F. H. et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur. Urol. 48, 922-930 (2005).